DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Mok TSK, Wu Y, Nakagawa K et al.
Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the phase III, randomised IMPRESS study.
Ann Oncol 2014; abstr LBA2_PR
25 (Suppl. 04)
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.